Minoryx Therapeutics
VerifiedClinical stage biotech company focusing on the development of novel therapies for orphan CNS diseases with high unmet medical needs
Launch date
Employees
Ownership
Firm valuation
$102—153m (Dealroom.co estimates May 2022.)
Mataró Catalonia (HQ)
Financials
Edit| EUR | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022E |
|---|---|---|---|---|---|---|---|
| Revenues | <1m | <1m | <1m | 2m | 4m | - | - |
| % growth | 500 % | 400 % | (83 %) | 3900 % | 100 % | - | - |
| EBITDA | <1m | <1m | <1m | <1m | (1m) | - | - |
| % EBITDA margin | (1000 %) | (33 %) | (1200 %) | 5 % | (25 %) | - | - |
Source: Company fillings or news article
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - Not yet verified | |
| N/A | Spinout | ||
| N/A | €2.3m | Grant Not yet verified | |
| €1.5m | Series A | ||
| €1.6m | Early VC | ||
| €19.4m | Series A | ||
| €3.1m | Grant | ||
* | €21.3m | Series B | |
| €25m | Grant | ||
* | $25.5m | Debt | |
* | $25.5m | Series C | |
| Total Funding | $105m | ||
Recent News about Minoryx Therapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.